Drugs / mCD19-CAR-CD28-CD3-zeta
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07162038 | Nov 2025 → Nov 2030 expected | hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mCD19-CAR-CD28-CD3-zeta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162038 ↗ |
| Known as | anti-CD19 CAR | “mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)” NCT07162038 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T-cell therapy takes immune cells and changes them in a lab to better recognize and target certain cancers.” NCT07162038 ↗ |
| Route | Intravenous | “Both the donor bone marrow cells and CAR-T-cells will be given through a tube inserted into a vein.” NCT07162038 ↗ |